Hotspot issues and considerations in multi-gene testing in breast cancer
Multigene testing serves as a cornerstone of precision oncology, reshaping the holistic management of breast cancer across its continuum. In early-stage HR-positive/HER2-negative (HR+/HER2-) disease, genomic assays such as MammaPrint® and Oncotype DX® enable refined risk stratification; however, their evidence bases di...